NCT00894738 is a clinical trial of Testing (MRS, US, DEXA, blood tests) in Mental Disorders, sponsored by Washington University School of Medicine.

Who is sponsoring NCT00894738?

NCT00894738 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT00894738?

Interventions in NCT00894738: Testing (MRS, US, DEXA, blood tests).

What condition does NCT00894738 study?

NCT00894738 studies Mental Disorders.

Is NCT00894738 still recruiting?

NCT00894738 is currently completed. Last updated 6 June 2019.

Are results published for NCT00894738?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-06-06 · How we verify

NCT00894738

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers of Cardiometabolic Risk in Children Treated With Antipsychotics: A Preliminary Study of Direct Measures

Completed Results posted Last updated 6 June 2019

What this trial tests

trial testing Testing (MRS, US, DEXA, blood tests) in Mental Disorders in 44 participants. Completed in 1 June 2016.

Timeline

1 January 2010

Primary endpoint
31 March 2016

1 June 2016

Quick facts

Lead sponsor	Washington University School of Medicine
Status	Completed
Study type	OBSERVATIONAL
Enrollment	44
Start date	1 January 2010
Primary completion	31 March 2016
Estimated completion	1 June 2016
Sites	1 location across United States

Drugs / interventions tested

Testing (MRS, US, DEXA, blood tests)

Conditions studied

Mental Disorders — all drugs for Mental Disorders →

Sponsor

Washington University School of Medicine

Who can join

Adults 6 to 18, any sex, with Mental Disorders. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Carotid Artery Intima-media Thickness Measured by Ultrasonography. Primary · Week 1

Group	Value	95% CI
Antipsychotic-Treated	0.508	± 0.053
Healthy Control	0.519	± 0.048

Intrahepatic Triglyceride Content (IHTG) Measure by Liver Magnetic Resonance Spectroscopy. Primary · Week 1

Group	Value	95% CI
Antipsychotic-Treated	2.48	± 3.03
Healthy Control	1.57	± 1.37

Sponsor's own description

The proposed study aims to begin the multi-step process of establishing the reliability and validity of hepatic triglyceride content (HTGC) and carotid artery intima-media thickness (IMT) as biomarkers of cardiometablic risk in children treated for mental illness. The distribution of HTGC and carotid IMT-proximate indicators of cardiometabolic risk-across a range of dual-energy X-ray absorptiometry (DEXA)-measured adiposity in children treated with antipsychotic agents will be characterized in comparison to healthy, untreated, non-psychiatric controls, in order to estimate effect sizes for future studies incorporating these markers. The ability of HTGC and IMT to predict cardiometabolic risk as measured by commonly-used laboratory tests, such as fasting lipids, liver function tests, C-reactive protein and serum fibrinogen, will be assessed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment.
Nicol GE, de las Fuentes L, Riek AE, Bernal-Mizrachi C, et al · · 2015 · cited 1× · PMID 26186300 · DOI 10.1210/jc.2015-2119

Verify or expand the search:

Other recruiting trials for Mental Disorders

Currently open trials in the same condition.

NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT06810076 — Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care · NA · active not recruiting
NCT06387290 — Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits · Phase 3 · recruiting
NCT06673966 — Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia · recruiting
NCT06930547 — Effectiveness of Smoking Cessation Education · NA · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00894738 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 6 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00894738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing